



06 30-06

DAC
JFW

EXPRESS MAIL LABEL NO.EV 687 637 727 US


PETITION FOR CERTIFICATE OF CORRECTION Address to: Mail Stop DAC Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	GRUE-003
	First Named Inventor	BUJARD, HERMANN
	Patent Number	6,933,130
	Issue Date	August 23, 2005
	Application Number	09/269,874
	Filing Date	August 2, 1999
	Title:	<i>"RECOMBINANT PROCESS FOR PREPARING A COMPLETE MALARIA ANTIGEN GP190/MSP1"</i>

Sir:

Transmitted herewith for filing is a Certificate of Correction for the above-identified patent. Please correct the title of the patent to read **"RECOMBINANT PROCESS FOR PREPARING A COMPLETE MALARIA ANTIGEN GP190/MSP1"**. Enclosed is a copy of the first page of the specification as filed on October 2, 1997 and a Request to Correct Filing Receipt as filed on July 7, 2000.

It is believed that no fee is due since the error was made by the Patent and Trademark Office. However, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. § 1.20, which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 order number GRUE-003.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

By: 
Paula A. Borden
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Fax: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,933,130
DATED : August 23, 2005
INVENTOR(S) : BUJARD, HERMANN, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

The title of the application should read:

--"RECOMBINANT PROCESS FOR PREPARING A COMPLETE MALARIA ANTIGEN
GP190/MSP1"--

MAILING ADDRESS OF SENDER:

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303


PATENT NO. 6,933,130


No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name	Mathew Otts		
Signature		Date	July 7, 2000
REQUEST FOR CORRECTED FILING RECEIPT Address to: Assistant Commissioner for Patents Washington, D.C. 20231		Attorney Docket	GRUE-003
		First Named	Bujard, et al.
		Application Number	09/269,874
		Int'l Filing Date	October 2, 1997
		Group Art Unit	1641
		Examiner Name	N/A
		Title	



Sir:-

A filing receipt for the above-identified patent application has been issued by the U.S. Patent and Trademark Office (copy attached) and has been found to contain the following error(s):


- (1) The title reads "Recombinants Process For Preparing a Complete Malaria Antigen GP190/MSPI", but should read --Recombinant Process For Preparing a Complete Malaria Antigen GP190/MSPI--.

It is believed that the error was made by the U.S. Patent and Trademark Office since the first page of the specification indicates that the title is "Recombinant Process For Preparing a Complete Malaria Antigen GP190/MSPI". Copies of all of the above documents are attached.

No fee is believed due in connection with this request. However, if for any reason a fee is found to be necessary, the Commissioner is authorized to charge such fee to Deposit Account No. 50-0815.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: July 7, 2000

By: 
Paula A. Borden
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

DOCKETED
filed 7/7/2000

Recombinant process for preparing a complete malaria antigen, gp190/MSP1

The invention concerns a recombinant manufacturing process for the complete malaria antigen gp190/MSP1, as well as separate naturally-occurring domains and parts of the same, by expression of a synthetic DNA sequence. The invention concerns in addition the DNA sequences produced by the process and the host organisms used for the expression of the DNA sequences. In addition the invention concerns the use of the complete malaria antigen as well as parts thereof as a vaccine for immunization against malaria.

Finally the invention under consideration concerns a stabilization process for AT-rich genes, as well as stabilized genes which are characterized by a reduced AT content.

Malaria is one of the most significant infectious diseases in the world. According to WHO reports, in 1990 40% of the world population in 99 countries was exposed to the risk of malaria. At the same time its distribution is enormously on the increase. This may be ascribed above all to intensive development of resistance in the parasites causing malaria, promoted by the recommendation and use as prophylactics of the drugs intended for treatment. Besides the search for new and effective chemotherapeutic agents hope is nowadays directed towards the development of vaccines, since people in areas of the world where malaria is epidemic do manage to develop some kinds of immunity. As well as a natural resistance to malaria, such as that found in heterozygous carriers of the sickle-cell gene and people with thalassaemia and glucose-6-phosphate dehydrogenase deficiency, in the course of malarial infection in humans immune mechanisms can be stimulated which express themselves in a heightened capacity for resistance to the Plasmodia. Consequently the course of the disease in populations exposed to severe epidemics is generally less threatening than in persons exposed to the infection less frequently or for the first time.

The main problem in the development of a vaccine is the identification of an antigen which can induce protective immunity, since there is no easily accessible well-defined animal model available for the four parasites affecting man. The organism causing malaria belongs to the Plasmodium group, of which infection with one of the four parasites *Plasmodium vivax*,